Abstract l Background: FK506 has been used for treatment of cell-mediated immune disorders such as graft rejection in transplantation or Behçet disease. To evaluate the effectiveness of FK506 in another ocular disease model, we injected FK506 in rats with experimental allergic/immunemediated blepharo conjunctivitis (EAC) the induction mechanism of which depends on cell-mediated immunity. l Methods: Lewis rats were immunized with ovalbumin (OVA) in emulsion of complete Freund's adjuvant (CFA). We injected 2 (n=6), 20 (n=6) or 200 (n=5) g of FK506 intramuscularly daily from the day of immunization (day 0) to day 6. Control rats were not treated with FK506 (n=4). In addition, we injected 200 g of FK506 from day 7 to day 13 (n=12) to compare the timing of FK506 administration (day 0 to day 6, n=12; control, n=12). Twenty-one days after immunization, all rats were challenged with OVA by eye drops, and 24 h later they were killed after clinical evaluation and their eyes, blood and draining lymph nodes were harvested for histology, antibody titers and proliferation assay or flow cytometric analysis. In another set of experiments, rats that had received OVA-primed lymph node cells did (n=9) or did not (n=9) receive additional FK506 by injection daily for 4 days. Four days after transfer, these rats were challenged with OVA and evaluated as mentioned. To investigate possible suppression of disease by topical administration of FK506, both actively immunized and passively immunized rats received OVA together with 0.3% (weight/volume) of FK506 (n=16) or vehicle (n=10) by eye drops and 24 h after challenge, rats were evaluated as mentioned. 
Inhibitory effects of FK506 on the development of experimental allergic/immune-mediated blepharoconjunctivitis in Lewis rats by systemic but not by topical administration Abstract l Background: FK506 has been used for treatment of cell-mediated immune disorders such as graft rejection in transplantation or Behçet disease. To evaluate the effectiveness of FK506 in another ocular disease model, we injected FK506 in rats with experimental allergic/immunemediated blepharo conjunctivitis (EAC) the induction mechanism of which depends on cell-mediated immunity. l Methods: Lewis rats were immunized with ovalbumin (OVA) in emulsion of complete Freund's adjuvant (CFA). We injected 2 (n=6), 20 (n=6) or 200 (n=5) g of FK506 intramuscularly daily from the day of immunization (day 0) to day 6. Control rats were not treated with FK506 (n=4). In addition, we injected 200 g of FK506 from day 7 to day 13 (n=12) to compare the timing of FK506 administration (day 0 to day 6, n=12; control, n=12). Twenty-one days after immunization, all rats were challenged with OVA by eye drops, and 24 h later they were killed after clinical evaluation and their eyes, blood and draining lymph nodes were harvested for histology, antibody titers and proliferation assay or flow cytometric analysis. In another set of experiments, rats that had received OVA-primed lymph node cells did (n=9) or did not (n=9) receive additional FK506 by injection daily for 4 days. Four days after transfer, these rats were challenged with OVA and evaluated as mentioned. To investigate possible suppression of disease by topical administration of FK506, both actively immunized and passively immunized rats received OVA together with 0.3% (weight/volume) of FK506 (n=16) or vehicle (n=10) by eye drops and 24 h after challenge, rats were evaluated as mentioned. l Results: Development of disease, induced by either active or passive immunization, was inhibited in the group treated with 200 g of FK506, regardless of timing of administration. Cellular proliferative responses to OVA were inhibited only in this group. Flow cytometry demonstrated a decrease of about 20% in the proportion of all cells made up by CD4-positive T cells. Topical administration of FK506 inhibited the development of EAC, though not significantly. l Conclusions: Systemic treatment with 200 g of FK506 either in the induction or the effector phase inhibits the development of EAC in Lewis rats. Topical administration is not so effective as systemic administration.
Introduction
Allergic conjunctivitis is a group of diseases characterized by hypersensitive immune-mediated inflammation against exogenous antigens in the conjunctiva [6] . Clinical and experimental reports have demonstrated that IgE-mediated immediate responses are dominant mechanisms for the development of this disease [5, 15] . Although humoral immunity is the major effector mechanism for the development of allergic conjunctivitis, cellular immunity is also thought to be involved in the development of certain kinds of allergic conjunctivitis such as vernal keratoconjunctivitis (VKC) [1, 3] . Recently, we demonstrated the essential role of cellular immunity for the induction of experimental allergic/immune-mediated blepharoconjunctivitis (EAC) in Lewis rats [8] . The histopathological features of EAC are similar to those of VKC. In our system, EAC was induced either by active immunization or adoptive transfer of allergen-primed lymph node cells.
FK506 is known to suppress cellular immunity by inhibiting production of cytokines and IL-2 receptor expression of T cells, leading to reduction in number and function of CD4-positive T cells [2, 18] . FK506 exerts its effects at 10±100 times lower concentrations than cyclosporin A (CsA) [19] . Therefore, it has been used both in experimental animals and in humans for treatment of cell-mediated immune disorders such as graft rejection in organ transplantation [20, 21] .
Concerning eye diseases, Mochizuki et al. extensively studied the effects of systemic administration of FK506 in experimental autoimmune uveitis [7, 12] and in patients with uveitis [17] . In addition, they investigated the effect of topical application of FK506 or CsA on endotoxin-induced uveitis [9] or corneal allograft transplantation [10] and demonstrated the effectiveness in terms of suppression of development of disease.
For the treatment of allergic conjunctivitis, anti-histamine drugs are the first choice, and topical steroid therapy is selected for severe cases [11] . Recently, however, immunosuppressive drugs targeted to T cells, such as cyclosporin A or FK506, were discovered, and trials of topical administration demonstrated that these drugs were just as effective as corticosteroids [11] . In addition to allergic conjunctivitis, treatment of FK506 effectively suppressed the development of allergic diseases such as contact dermatitis [13, 14] . These reports prompted us to investigate the inhibitory effects of either systemic or topical administration of FK506 on EAC in Lewis rats, in which cellular immunity is dominantly involved.
Materials and methods

Rats
Six-to 8-week-old male Lewis rats were purchased from a commercial source (Seac Yoshitomi, Fukuoka, Japan) and maintained in a specific pathogen-free animal facility at Kochi Medical School. All animal procedures conformed to institutional guidelines and the ARVO Resolution on Use of Animals in Research.
Reagents
FK506 was provided by Fujisawa Pharmaceutical, Osaka, Japan. For systemic administration by intramuscular injection, FK506 was suspended in phosphate-buffered saline (PBS) to achieve the required concentrations. For topical administration by eye drops, 0.3% (weight per volume) of FK506 and vehicle were prepared by the company.
Immunization
Rats were injected with 100 g of ovalbumin (OVA; grade V, Sigma Immunochemicals, St. Louis, Mo.) emulsified with complete Freund's adjuvant (CFA; Yatoron, Tokyo, Japan) in a final volume of 100 l in their left hind footpads.
Experimental protocol
Active immunization (dose-response)
The day of immunization was regarded as day 0. Tested groups of rats received 2 g (n=6), 20 g (n=6) or 200 g (n=5) of FK506 daily from day 0 to day 6 by intramuscular injection. Control rats were not treated with FK506. Twenty-one days after immunization, all rats were challenged with OVA by eye drops as previously reported. Twenty-four hours later, they were clinically evaluated, killed, and eyes, including lids, blood, and draining lymph nodes, were harvested for histology, ELISA, proliferative responses and flow cytometry.
Active immunization (timing for FK506 administration)
Procedures were the same as described above except for the timing of FK506 injection. Tested groups of rats received 200 g of FK506 daily from day 0 to day 6 (early induction phase; group 1, n=12), and from day 7 to day 13 (late induction phase; group 2, n=12). Group 3 were control rats without FK506 treatment (n=12).
Passive immunization by adoptive transfer of OVA-primed lymph node cells (systemic administration)
Cells from immune inguinal lymph nodes were harvested 14 days after immunization. Cells were washed three times and then stimulated with OVA for 3 days as detailed in our previous report [8] . 3010 6 stimulated cells were injected into syngeneic male Lewis rats (recipients) by intravenous injection. Tested groups of rats received daily intramuscular injections of 200 g of FK506 from the day of transfer to the day of challenge (n=9; control n=9). Four days after transfer, recipients were challenged with OVA by eye drops; 24 h later, the same procedures as described above [Active immunization (dose-response)] were performed.
Passive immunization by adoptive transfer of OVA-primed lymph node cells (topical administration) EAC was induced either by active or passive immunization of cell transfer following the same procedures as above. Tested groups of rats received 10 l of FK506 by eye drops. Twenty-four hours before challenge and 1, 2, 3, 4, 6, and 12 h after challenge, they received Above: not treated at all; below: treated with 200 g of FK506 from day 0 to day 6. Rats were actively immunized with OVA and challenged with OVA by eye drops as described in Materials and methods. Magnification 320 10 l of FK506 by eye drops (n=16). Control rats were treated with vehicle by eye drops (n=10). Twenty-four hours later, all rats were clinically evaluated and killed for histological study.
Clinical grading and histological studies of conjunctiva
The clinical scoring system used was based on our previous report [8] . In brief, each eye was assessed for the findings of lid swelling and discharge, and each finding was scored as one point. Ocular changes were also examined histologically. After clinical evaluation, eyes, including the lids, were fixed in 10% buffered formalin and embedded in paraffin. Ten-micrometer sections were cut and stained with hematoxylin and eosin. All the infiltrated cells which we could not categorize as macrophages or lymphocytes by this staining were counted in the palpebral conjunctiva per field, using an eye-piece grid at 400 magnification. The data were represented as cells/mm 2 . By this method, less than 5 cells/mm 2 were counted in the normal conjunctiva of the rat.
Proliferative responses of draining lymph node cells Lymph nodes or spleens from two or three rats were combined in each group and experiments were repeated as recorded. Lymph node cells were used for experiments of active immunization, splenocytes for those of passive immunization. Lymphocyte proliferation assays were set up in quadruplicate in 96-well flat-bottom plates. Either lymph node cells or splenocytes (310 5 cells/well) were cultured in a final volume of 0.2 ml RPMI 1640 medium supplemented with 5% FCS, 2-ME (510 5 M), l-glutamine (2 mM), penicillin (100 U/ ml) and streptomycin (100 g/ml). Cells were stimulated with OVA at final concentrations of 0.1, 1, 10, or 100 g/ml or with concanavalin A (Con A; Sigma Immunochemicals, St. Louis, Mo.) at 1 g/ml or purified protein derivative (PPD, Japan BCG, Tokyo, Japan) at 1 g/ml. After incubation for 72 h at 37 C in a humidified atmosphere with 5% CO 2 , cultures were pulsed for 16 h with 0.5 Ci/well of 3 Hthymidine (Japan Atomic Energy Research Institute, Tokai, Japan). Cultures were then harvested and the radioactivity was measured by standard techniques. Data were expressed as stimulation indices.
Anti-OVA antibody titers of serum from rats Serum was collected from each rat via cardiac puncture at the time of death. Serum antibody levels against OVA were measured by direct ELISA. OVA (500 ng/well) were absorbed to 96-well plates for 2 h at 37 C. The plates were washed with PBS-Tween, and serially diluted serum samples were added to the wells. Bound antibody was detected by peroxidase-conjugated anti-IgG (Nordic Immunological Laboratories, Tilburg, The Netherlands). The plates were developed using 3,3 Â ,5,5 Â -tetramethylbenzidine base (TIMB-ELISA; Gibco BRL, Gaithersburg, Md.), and the optical density (OD) for each well was read at 610 nm.
Flow cytometry
Cells were stained with following anti-rat antibodies (Abs). Anti-CD4 and anti-CD8 (Pharmingen, San Diego, Calif.) are FITC labeled. Anti-CD3 and anti-CD25 (Pharmingen), anti-I-A (OX-3) and anti-CD45RA (OX-33) (Serotec, Oxford, UK), and antiCD11a (LFA-1a) (Caltag Laboratories, Burlingame, Calif.) are biotin-labeled. The cells were incubated for 45 min on ice with the primary Abs above (0.02±2 g/210 6 cells) and washed with cold 5% FCS-PBS. Streptoavidin-PE (Pharmingen) was added to cells stained with biotin-conjugated Abs for 10 min and then the cells were washed again. The cells were then analyzed using FACScan (Becton Dickinson, Mountain View, Calif.).
Statistical analysis
Statistical comparison of the number of infiltrated cells between two groups was performed using Student's t-test.
Results
Systemic FK506 treatment: dose response
To test the dose required to inhibit the induction of EAC, we injected three different doses of FK506 (2 g, 20 g and 200 g) from day 0 to day 6 intramuscularly. As shown in Fig. 1, only (Fig. 3a) . There was no clear difference in number of lymph node cells recovered from each rat among all the groups (Table 1) . Although there were no remarkable differences in the proliferative responses for Con A among these four groups of rats, lymph node cells from rats treated with 200 g of FK506 exhibited diminished proliferative responses against PPD compared to those from other groups ( Table 1) . To evaluate the influence of the timing of FK506 administration of the inhibition of the induction of EAC, we injected 200 g of FK506 intramuscularly daily, either from day 0 to day 6 or from day 7 to day 13. No animals except for one rat in group 1 and one in group 2 showed any clinical pathologic changes. In contrast, almost all of the control rats had discharge and/or lid swelling (Fig. 2) . Compared to the control group (group 3), both proliferative responses (Fig. 3a, b) and IgG production specific to OVA (Fig. 3c) were inhibited in group 1 and group 2. Immune responses against OVA were profoundly suppressed in group 1 compared to group 2 (Fig. 3b, c) .
Flow-cytometric analysis of lymph node cells of FK506-treated rats
Lymph node cells from group 1 and group 3 were tested for their surface markers by FACscan analysis. As shown in Table 2 , a 20% decrease was detected in both CD3-or CD4-positive cells in the FK506-treated group compared to the control group. In contrast, percentages of cells positive for CD45RA, which is a B cell marker, relatively increased. Taking the data of Table 1 into consideration, FK506 inhibited the increase of CD4-positive T cells in vivo, while B cells were not affected.
Systemic FK506 treatment inhibited EAC by adoptive transfer of OVA-pimed lymph node cells
To investigate the effects of FK506 on the effector phase of EAC, we injected 200 g of FK506 each day from the day of transfer to the day of OVA challenge. Cellular infiltration was significantly suppressed (P`0.001) by treatment with 200 g of FK506 (Fig. 4a) . Proliferative re- a b c sponse of splenocytes from recipients treated with FK506 was also inhibited compared to the control rats (Fig. 5 ).
Topical FK506 treatment by eye drops partially suppressed the severity of EAC The data presented above show that systemic treatment with FK506 was effective for suppression of EAC. We tested the possibility of suppression of EAC by treatment with topical FK506 in the form eye drops. In this study, we used both active immunization and passive immunization by adoptive transfer of OVA-primed lymph node cells. The number of cells infiltrated, induced by either active immunization (data not shown) or passive immunization (Fig. 4b) , was diminished, though not significantly so (P=0.06).
Discussion
The data recorded here demonstrated the inhibitory effects of FK506 administration on the development of EAC using both active and passive immunization systems. Although the nature of the target antigens (autoantigen versus exogenous antigen) differed between EAU and EAC in Lewis rats, the inducing mechanism of both diseases, which is mediated by cellular immunity [8, 16] , is thought to be similar, because transfer of CD4-positive T cell line specific to OVA 323±339 peptide induced EAC after challenge with OVA in the form of eye drops (unpublished results). As injection of FK506 effectively inhibited the development of EAU [12] , we tested the possible effects of FK506 on the suppression of EAC. The required dose for suppression of EAC by systemic treatment during early induction phase was 200 g (Fig.  1a) the same dose as previously reported in the system of EAU in Lewis rats [12] . Dose dependency was observed in the suppression of disease as well as the inhibition of immune responses (Figs. 1a, 3a) . As shown in Ta- To compare the effects of timing of FK506 administration at the same amount, we injected 200 g of FK506 either during early induction phase (from day 0 to day 6) or late induction phase (from day 7 to day 13). At this dose, there was no remarkable difference in inhibitory effects on EAC between the two phases (Fig. 2) . Although cellular proliferative responses were inhibited in both groups, (Fig. 3a, b) antibody production was not suppressed in the group treated during late induction phase (Fig. 3b,  c) . These data further supported our previous report that cellular immunity, rather than humoral immunity, is involved in the development of EAC [8] . In addition, the data could be interpreted as indicating that once B cells were primed with OVA, their function could not be disturbed by FK506, while function of T cells could be inhibited by FK506 even after being primed.
Although the number of CD4-positive T cells in the group treated with 200 g of FK506 is lower than in the control group, there were definitely still CD4-positive T cells in the former group (Table 2) . Previous reports demonstrated that the frequency of soluble antigen-specific cells in immunized animals was in general lower than 1% [4] , and therefore, a 20% decrease in CD4-positive T cells in the FK506-treated group may also depend on a decrease in the cell population not specific to OVA. Taking Table 1 into consideration, it could be regarded that not only OVA-specific but also OVA-unrelated CD4-positive T cells were disturbed by FK506 treatment. Therefore, the suppressive effects on EAC of the systemic administration of FK506 could be partially attributed to a decrease in OVA-unrelated CD4-positive lymph node cells as well as OVA-specific cells.
It is also of note that CD8-positive cells were not affected by FK506, although we did not test the function of these cells. As FK506 specifically blocks the signaling pathway initiated by T cell receptor [2, 18, 19] , CD4-positive macrophages should not be affected. From these data, as previously reported [12] , FK506 specifically suppressed CD4-positive T cells without affecting other phenotypes of cells such as CD8-positive T cells and macrophages.
Although the data on FK506 treatment in actively immunized rats indicated efficient suppression of EAC by FK506, it could be considered that this inhibition might depend on the suppression of the maturation of CD4-positive T cells during the induction stage. To test the effectiveness of FK506 during the effector phase, we injected FK506 into rats that had received OVA-primed lymph node cells. Even though we did not clarify whether FK506 inhibited the functions of donor cells, recipient cells or both, FK506 treatment during the effector phase inhibited the development of EAC (Fig. 4a) as well as cellular proliferative responses against OVA (Fig. 5) . Including the data of actively immunized rats, we concluded that systemic administration of FK506 is effective for inhibition of EAC in both the induction and the effector phases.
Because EAC is a T cell-mediated disease [8] (unpublished results), and FK506 should be easily available to the conjunctiva in the form eye drops, there is a good possibility that topical administration of FK506 might be effective for inhibition of disease. Some inhibition, albeit not statistically significant, was observed for treatment with topical FK506 (Fig. 4b) . Although we used FK506 at one particular concentration (0.3% weight per volume), this concentration was demonstrated to be effective for suppression of endotoxin-induced uveitis [15] . With respect to cyclosporin A, a 0.4% concentration was effective to suppress the development of mast cell-mediated conjunctivities [22] . However, the induction mechanism of EAC is different, and therefore this concentration of topical FK506 may not be high enough to inhibit EAC.
Dose-dependency of FK506 on inhibition (Fig. 1a , Table 1) indicated that the amount administered in vivo is important for the effectiveness of FK506. The route of administration is also important, because topical application by eye drops must affect infiltrated cells more directly. Concerning the adoptive transfer system in this study, the total amount of FK506 given by systemic administration was 1 mg, while that by topical was approximately 4.2 g. Therefore, a possible explanation for differences in effectiveness of FK506 between systemic and topical administration is that systemic administration may lead to a higher and continuous FK506 concentration in blood and also to a higher concentration of FK506 in the conjunctiva.
The data presented here demonstrate, for the first time, the effective inhibition by FK506 of the development of experimental allergic conjunctivitis induced by exogenous antigens. From these data, FK506, especially by systemic administration, may be a candidate for the therapy of certain types of cell-mediated conjunctivitis in humans. In addition, topical administration of FK506, in combination with other drugs such as topical steroids, may be effective in the treatment of allergic conjunctivitis.
